The DOI matches its Crossref record; 201 of the 201 references it cites were found in a registry or an index.
Current and emerging treatment options for endometriosis
Abstract
INTRODUCTION: Pharmacotherapy has a pivotal role in the management of endometriosis with long-term treatments balancing clinical efficacy (control of pain symptoms and prevention of recurrence of the disease after surgery) with an acceptable safety profile. Treatment choice is based on several factors including age and patient preference, reproductive plans, intensity of pain, severity of disease and incidence of adverse effects. AREAS COVERED: The aim of this review is to provide the reader with a complete overview of drugs that are currently available or are under investigation for the treatment of endometriosis highlighting on-going clinical trials. EXPERT OPINION: Almost all of the available treatment options for endometriosis suppress ovarian function and are not curative. Combined oral contraceptives and progestins are commonly administered to these patients in order to ameliorate pain symptoms. Gonadotropin-releasing hormone-agonists are prescribed when first-line therapies are ineffective, not tolerated or contraindicated. Aromatase inhibitors should be reserved only for women who are refractory to other treatments. Amongst the drugs under development, gonadotropin-releasing hormone antagonists have shown the most promising results. Presently, are a number of potential therapies currently in pre-clinical or early clinical studies which may alter treatment strategies in the future although further studies are necessary.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, hormonal treatment also impedes conception, excluding this approach in women wishing to conceive [1,4].”
From Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review (2021) · cites this paper as [4]
Citations
Cites
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
ESHRE guideline: management of women with endometriosis
Dunselman, G. A. J., Vermeulen, N., Becker, C., Calhaz-Jorge, C., D'Hooghe, T., De Bie, B., Heikinheimo, O., Horne, A. W., Kiesel, L., Nap, A., et al. (2014) · Human Reproduction · doi:10.1093/humrep/det457 · Cited by 2,211
Erasers of Histone Acetylation: The Histone Deacetylase EnzymesPreprint
Seto, E., & Yoshida, M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018713 · Cited by 2,105
Endometriosis: pathogenesis and treatment
Vercellini, P., Viganò, P., Somigliana, E., & Fedele, L. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.255 · Cited by 1,940
Pathogenesis and pathophysiology of endometriosis
Burney, R. O., & Giudice, L. C. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2012.06.029 · Cited by 1,590
(1927) · PubMed Central · Cited by 1,008
Clinical Management of Endometriosis
Falcone, T., & Flyckt, R. L. (2018) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000002469 · Cited by 582
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
Taylor, H. S., Giudice, L. C., Lessey, B. A., Abrao, M. S., Kotarski, J., Archer, D. F., Diamond, M. P., Surrey, E., Johnson, N. P., Watts, N. B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700089 · Cited by 511
Strowitzki, T., Marr, J., Gerlinger, C., Faustmann, T., & Seitz, C. (2010) · Human Reproduction · doi:10.1093/humrep/dep469 · Cited by 381 · cited 1×
“In these studies, the severity of women’s pain symptoms decreased significantly without inter-group differences [39,40].”
BackgroundPetta, C. A., Ferriani, R. A., Abrao, M. S., Hassan, D., Rosa e Silva, J. C., Podgaec, S., & Bahamondes, L. (2005) · Human Reproduction · doi:10.1093/humrep/deh869 · Cited by 363 · cited 1×
“75 mg every 3 months) in women with endometriosis, reporting a significant similar reduction in the intensity of pain symptoms with both regimens [57,58].”
Background
Research works printed but not linked: 4
- Brown J, Crawford TJ, Allen C, et al. Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev. 2017 Jan 23;1:CD004753. PubMed PMID: 28114727.
- Grandi G, Mueller M, Bersinger NA, et al. Does dienogest influence the inflammatory response of endometriotic cells? A Systematic Review. Inflamm Res. 2016 Mar;65:183–192. PubMed PMID: 26650031
- Le Bouedec G, Kauffmann P, Pingeon JM, et al. [Post-menopausal endometriosis developed during tamoxifen treatment]. Rev Fr Gynecol Obstet. 1991 May;86(5):407–410. PubMed PMID: 1871504.
- 10.1038/nrendo.2013.255 · DOI · Paper page
Cited by
Sorted by citations
Rethinking mechanisms, diagnosis and management of endometriosis
Chapron, C., Marcellin, L., Borghese, B., & Santulli, P. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0245-z · Cited by 1,084
Donnez, J., & Dolmans, M.-M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10051085 · Cited by 182
Endometriosis, an Ongoing Pain—Step-by-Step Treatment
Mechsner, S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11020467 · Cited by 103
“Furthermore, in case of ongoing pain, also under GnRha, aromatase inhibitor treatment (with or without progestin, COC, or GnRH analog, significantly reduced pain compared with GnRH analog alone [18].”
BackgroundCaruso, S., Iraci, M., Cianci, S., Vitale, S. G., Fava, V., & Cianci, A. (2019) · Journal of Pain Research · doi:10.2147/jpr.s207599 · Cited by 73
A comprehensive review of hormonal and biological therapies for endometriosis: latest developments
Barra, F., Grandi, G., Tantari, M., Scala, C., Facchinetti, F., & Ferrero, S. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1581761 · Cited by 69
Self-citation
Metadata
- Authors
- Ferrero, S., Evangelisti, G., & Barra, F.
- Affiliations
- Ospedale Policlinico San Martino (IT)
- Corresponding author
- Ferrero, Simone
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2018-07-03
- Volume
- 19
- Issue
- 10
- Pages
- 1109-1125
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2872842744
- Cited by
- 152
- References
- 201
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 17 · 2023: 21 · 2022: 19 · 2021: 30 · 2020: 19 · 2019: 16 · 2018: 7
- FWCI
- 2.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Pharmacotherapy (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Ectopic Pregnancy Diagnosis and Management
- Health Sciences › Medicine › Obstetrics and Gynecology › Gynecological conditions and treatments
- Keywords
- endometriosis, pharmacotherapy, ovarian suppression, combined oral contraceptives, progestins, GnRH agonist, GnRH antagonist, aromatase inhibitors, pain management, drug development, clinical trials
- MeSH terms
- Anti-Inflammatory Agents, Non-Steroidal, Drug Combinations, Endometriosis, Ethinyl Estradiol, Female, Hormone Antagonists, Humans, Gonadotropin-Releasing Hormone, Norpregnenes, Progestins, Aromatase Inhibitors, Pain Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
